Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta)

NCT00216528 is registered in ClinicalTrials.gov with Janssen Korea, Ltd., Korea as lead sponsor.

NCT NCT00216528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00216528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta)
Lead sponsor
Janssen Korea, Ltd., Korea
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2005
Completion date
April 30, 2007
Enrollment
527 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia